Wendy Dixon

Biography

 Wendy Dixon brings more than 35 years of global biopharmaceutical leadership experience where, as a senior executive, she combined her technical and commercial background to direct the development, launch and growth of over 20 new pharmaceutical products, including many highly successful multibillion dollar global brands across multiple therapeutic areas including oncology, virology, immunology and neurology. Most recently, Dr. Dixon was a senior advisor to The Monitor Group, now Monitor Deloitte, a global consulting firm. From 2001 to 2009, she served as chief marketing officer and president, global marketing for Bristol-Myers Squibb, where she served on the executive committee. From 1996 to 2001, she was senior vice president, marketing at Merck & Co., with prior executive management positions at West Pharmaceuticals, Osteotech and Centocor, and various positions at SmithKline & French Pharmaceuticals (now GlaxoSmithKline) in marketing, regulatory affairs, project management and as a biochemist. Dr. Dixon currently serves on the board of directors of Alkermes, bluebird bio, Eleven Biotherapeutics and Incyte Corporation, and was formerly on the board of Dentsply International, Orexigen Therapeutics, Edimer Pharmaceuticals, Furiex Pharmaceuticals (sold to Actavis plc in 2014) and Ardea Biosciences, Inc. (sold to AstraZeneca plc in 2012). Dr. Dixon received her B.Sc., M.Sc. and Ph.D. from the University of Cambridge, England, U.K

Research Interest

 Dentsply International, Orexigen Therapeutics, Edimer Pharmaceuticals, Furiex Pharmaceuticals